Placeholder Banner

BIO Statement on Passage of Bipartisan Appropriations Package

February 3, 2026

WASHINGTON, D.C. –  John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement.

“The passage of the Mikaela Naylon Give Kids a Chance Act is a bipartisan victory for children and families living with rare diseases. We thank the bill’s House and Senate cosponsors and the countless patient advocates for their unwavering commitment to reauthorizing the Pediatric Priority Review (PPRV) program and to ensuring this bill crossed the finish line. The PPRV program provides critical incentives for rare disease research, and its reauthorization provides stability and confidence for biotech innovators who are leading the way in the discovery of breakthrough treatments.”

“For more than a decade, the PPRV program has incentivized the development of treatments for rare pediatric diseases at no cost to taxpayers, providing hope for families affected by devastating conditions who often previously had no options.  We thank Senators Mullin (R-OK) and Bennet (D-CO), Reps. McCaul (R-TX), Dingell (D-MI), Bilirakis (R-FL), Schrier (D-WA), Harshbarger (R-TN), Matsui (D-CA), Crenshaw (R-TX), Castor (D-FL), Weber (R-TX), and Trahan (D-MA) for their leadership on the bill.”

“This funding package also takes important first steps to rein in Pharmacy Benefit Managers (PBMs). For too long, these middlemen have driven up costs for patients, pocketing savings for themselves rather than passing them on. We look forward to continuing to work with Congress and the Administration to realize a 21st-century vision for healthcare access and affordability for American families. It is time to simplify our health care system, cut out the middlemen, and reduce out-of-pocket costs for patients.”

###

About the Biotechnology Innovation Organization (BIO)

BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org.
 

Discover More
WASHINGTON, D.C. – Phyllis Arthur, Executive Vice President and Chief of Global Health of the Biotechnology Innovation Organization (BIO), released the following statement on the loss of the United States’ measles elimination status.“The loss of…
Action plan outlines the policies needed to ensure that the biotechnology sector remains a driving force for America’s health, prosperity, national security, and geopolitical strengthWASHINGTON (November 10, 2026) - The Biotechnology Innovation…
Complaint argues HHS and CMS exceeded statutory authority; rule puts patient access, investment in future innovation, and America’s long-term biotechnology leadership at risk.WASHINGTON, DC & SAN DIEGO, CA & SAN FRANCISCO, CA - The…